Silence Therapeutics (NASDAQ:SLN) Given "Buy" Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Silence Therapeutics (NASDAQ:SLN - Free Report) in a research note published on Friday morning,Benzinga reports. The firm currently has a $75.00 price objective on the stock.

A number of other research analysts have also recently weighed in on the stock. The Goldman Sachs Group cut their price objective on shares of Silence Therapeutics from $6.00 to $4.00 and set a "sell" rating on the stock in a research report on Tuesday, March 4th. BMO Capital Markets cut their price target on shares of Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating on the stock in a report on Tuesday, March 4th. Morgan Stanley decreased their price objective on shares of Silence Therapeutics from $49.00 to $45.00 and set an "overweight" rating for the company in a research note on Wednesday, March 5th. William Blair reaffirmed an "outperform" rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. Finally, Chardan Capital reissued a "buy" rating and set a $55.00 price target on shares of Silence Therapeutics in a research note on Tuesday, December 10th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $40.67.

Remove Ads

Silence Therapeutics Trading Down 6.2 %

Shares of NASDAQ SLN traded down $0.28 during trading hours on Friday, hitting $4.22. 205,127 shares of the company traded hands, compared to its average volume of 302,646. The company's 50 day moving average price is $5.35 and its 200 day moving average price is $11.26. Silence Therapeutics has a 12 month low of $4.06 and a 12 month high of $27.72. The stock has a market capitalization of $126.30 million, a price-to-earnings ratio of -2.69 and a beta of 1.08.

Institutional Trading of Silence Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Woodline Partners LP raised its stake in Silence Therapeutics by 22.6% in the fourth quarter. Woodline Partners LP now owns 498,732 shares of the company's stock worth $3,431,000 after buying an additional 91,829 shares in the last quarter. Two Sigma Advisers LP lifted its position in shares of Silence Therapeutics by 18.6% during the fourth quarter. Two Sigma Advisers LP now owns 98,800 shares of the company's stock valued at $680,000 after buying an additional 15,500 shares during the last quarter. Redmile Group LLC boosted its holdings in shares of Silence Therapeutics by 26.3% in the 4th quarter. Redmile Group LLC now owns 2,399,317 shares of the company's stock valued at $16,507,000 after buying an additional 500,000 shares in the last quarter. Point72 Asset Management L.P. grew its position in shares of Silence Therapeutics by 35.3% in the 4th quarter. Point72 Asset Management L.P. now owns 633,100 shares of the company's stock worth $4,356,000 after buying an additional 165,300 shares during the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Silence Therapeutics by 50.5% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 128,990 shares of the company's stock valued at $887,000 after acquiring an additional 43,289 shares during the last quarter. 98.73% of the stock is owned by hedge funds and other institutional investors.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.